Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study - Yu, Jianfa; Bai, Yi; Cui, Zilin; Cheng, Chuanliang; Ladekarl, Morten; Cheng, Kai-Chi; Chan, Kai Siang; Yarmohammadi, Hooman; Mauriz, José L.; Zhang, Yamin (Journal of Gastrointestinal Oncology, 2024)